Visit ILCA | The world’s leading liver cancer meeting

At Eisai Europe, human health care is our goal. We give our first thoughts to patients and their families and helping to increase the benefits health care provides. We have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs.

To learn more, visit www.eisai.eu.

As part of the ILCA 2021 virtual programme, Eisai will be sponsoring a symposium and case studies workshop with leading experts to discuss the role of first-line monotherapy in unresectable hepatocellular carcinoma (uHCC). These sessions are aimed at healthcare professionals.

Session 1: Symposium – Saturday 4^th September 13:00 – 14:00 CET (and on demand)

The role of first-line monotherapy in a uHCC combination market

Join us for Eisai’s sponsored symposium where a panel of leading experts will discuss the role of first-line monotherapy in a rapidly evolving treatment landscape, followed by a live Q&A. With combination therapies expected to become the standard of care in first-line uHCC, our panel will cover a variety of topics including patient selection, clinical considerations, and the latest real-world evidence.

Session 2: Case studies workshop – Available on demand from Monday 6^th September

A case studies approach: The role of first-line monotherapy in a uHCC combination market

Our panel of experts will present cases depicting their clinical experiences of treating HCC patients with first-line monotherapy. This workshop-style session includes discussion around treatment selection, response to treatment and the place for monotherapy in the future treatment landscape.

 

This symposium and case study workshop have been organised and funded by Eisai Europe Ltd. Eisai Europe Ltd are a principal sponsor and has provided financial support for the organisation of ILCA 2021 but has had no influence over the scientific content of the meeting.

uHCC: unresectable hepatocellular carcinoma.

GL-LENA-21-00043 August 2021